A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer

NCT06211023 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

520

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: SHR-1921
DRUG: carboplatin
DRUG: carboplatin
DRUG: platinum-based doublet chemotherapy

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.